peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma

Partnering with Patient Organizations

At Hansa, we recognize the vital role patient advocacy groups (PAGs) play in advancing healthcare and supporting people with rare immunologic conditions. By partnering with non-profit PAGs and other non-profit organizations engaged directly or indirectly in healthcare and the support of patients Hansa aims to foster a more patient-centric approach to drug development, access and education. We are committed to fostering meaningful partnerships that empower patients and catalyze positive change. Together, we can make a difference in the lives of patients.

Our partnerships with patient advocacy organizations is guided by three fundamental principles:

  1. Independence: We respect the autonomy of patient advocacy groups and collaborate with them as equal partners.
  2. Respect and clarity of purpose: We value the perspectives and contributions of patient advocates. We actively listen, engage in open dialogue, and treat each other with respect.
  3. Transparency: Transparency is essential. We disclose any financial support provided to patient advocacy organizations.

The table below outlines the funding we provided to patient advocacy groups in 2023.

OrganizationCountryPurposeAmount
American Association of Kidney PatientsUSASponsorship of annual meeting and corporate membership25,000 USD
American Kidney FundUSAAdvocate Level Corporate Membership10,000 USD
American Kidney FundUSASponsorship of The Hope Affair Gala Dinner and CEO meeting9,500 USD
ANEDItalySupport for raising awareness amongst patients on high sensitisation in kidney transplantation20,000 EUR
EKHA Europen Kidney Health AllianceBelgiumSupport for EKHA's activities including the EU Kidney Forum, the EKHA Newsflash, the EKHA Working group and EKHA Network Event30,000 EUR
Kidney Research UKUKSupported the creation and publication of the 'Driving change – Report on the Health Economics of Kidney Disease in the UK'20,000 GBP
RenalooFranceSupport Renaloo's follow up actions and participation in the deployment of Transplant Plan Phase 1 to Phase 4 that ends in 202620,000 EUR